Navigation Links
Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
Date:10/13/2008

WALTHAM, Mass., Oct. 13 /PRNewswire/ -- Proteon Therapeutics is presenting new data today representing an important preclinical demonstration of the potential of PRT-201 to enhance outcomes in patients suffering from lower limb peripheral arterial disease (PAD). The presentation, entitled, "Local Catheter-Directed Elastase Therapy: A Novel Approach to Vessel Dilation and Restenosis," is being made at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. The new findings are being presented by F. Nicholas Franano, M.D., Chief Scientific Officer of Proteon Therapeutics.

"These preliminary non-clinical results showing vessel dilation with PRT-201 are very exciting," said Timothy P. Noyes, the Company's President and CEO. "We believe that local catheter delivery of PRT-201 immediately following balloon angioplasty procedures could potentially reduce the incidence of restenosis in PAD."

About Peripheral Arterial Disease

Peripheral artery disease, or PAD, is characterized by fatty plaque build-up in the arteries of the legs, which leads to poor blood flow and circulation. According to the American Heart Association, PAD affects eight million Americans and is a significant cause of both morbidity and death. Patients with PAD may experience muscle pain during walking, have wounds and ulcers that are slow to heal or, in the most severe cases, require amputation of the legs. Current interventional procedures, such as balloon angioplasty, are inadequate due to high rates of restenosis that restricts blood flow following treatment of the diseased vessel segments.

About Proteon Therapeutics

Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit http://www.proteontherapeutics.com.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
2. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
3. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
4. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
5. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):